Earnings call transcripts

Management emphasized improving brand execution and share momentum while acknowledging inflation, promotional sensitivity, and pet-food challenges remain unresolved.

Management framed Q1 as resilient execution amid temporary A2L, steel, and construction headwinds, with data centers and cash conversion strengthening the portfolio.

The new CEO framed recovery around food, guest experience and people, emphasizing dinner upgrades while portraying the existing plan as sound.

A predominantly built-to-order model cushioned a weakening market, but Southern California and rising costs lowered fourth-quarter expectations.

Management framed the quarter as a temporary demand setback offset by stronger execution, cost discipline, and improving order trends late in the period.

Management framed the year as a shift from wholesale-led growth toward a proprietary-IP and self-operated D2C model, accepting near-term volume pressure to protect brand value.

Management framed Q221’s durable off-drug efficacy as the first clinical evidence supporting its engineered disease-modifying mechanism.

Management framed Captivate as a complementary growth platform that diversifies NCM beyond cinema while extending its sales, local and programmatic capabilities.

Management framed the year as balance-sheet and cost restructuring through a Solana downturn, positioning Upexi to benefit if markets recover.

Management framed the quarter as steady execution despite worsening affordability, and reaffirmed volume-led land conversion over near-term margin maximization.

Management framed the half as a disciplined rebuild, with Bitcoin mining adding a second growth engine alongside entertainment and a path to profitability.

Management framed fiscal 2026 as a shift from foundational development toward commercialization, with AI datacom now the clear near-term priority.